

DETAILED ACTION

This application filed 07/13/2006 is a 371 of PCT/FR05/00084 01/14/2005.

Claims 1-14 and 16 are before the Examiner.

See Interview Summary.

In a telephonic interview with Stephen B. Maebius, 202 672-5569, on 01/30/2008, claim limitations with respect to optional substituents were discussed.

Agreement was reached on 03/10/2008 (see below).

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Stephen Maebius on 03/10/2008 and by facsimile transmission 03/10/2008.

REPLACE	Claim 1, line 6,	"1 to 20" with -1 to 6—
DELETE	Claim 1, line 7,	"optionally substituted with a hydroxyl, amino, ether or halogen group, or"
DELETE	Claim 1, line 8 and 9,	"said ring being optionally substituted with a hydroxyl, amino, ether or halogen group,"
REPLACE	Claim 2, line 4,	"1 to 20" with -1 to 6—
DELETE	Claim 2, line 4,	"optionally substituted with an ether or halogen group,"

DELETE, Claim 2, line 5, “, said ring being optionally substituted with an ether or halogen group”

REPLACE Claim 10, line 15, “1 to 20” with –1 to 6—

DELETE Claim 10, line 16, “optionally substituted with a hydroxyl, amino, ether, halogen group,”

DELETE, Claim 10, line 17 and 18, “, said ring being optionally substituted with a hydroxyl, amino, ether or halogen group”

Claims 1-14 and 16 are allowable.

Allowable Subject Matter

The following is a statement of reasons for the indication of allowable subject matter: The claims are drawn to pyranone compounds containing a 5-exo-halomethylene substitutions. A STN search for this structural core did not result in any hit. In addition, one of the instantly claimed compounds inhibited tumor growth with stated NIH standard (percent tumor growth/control <042%), and displayed maximum tolerated dose for single injection at 100 mg/kg in nude mice. The specification provides for chemical methods for making of the instantly compounds.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S. CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached on 8.30 AM - 4.30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571 0272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1625

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Nizal S. Chandrakumar

/D. Margaret Seaman/

Primary Examiner, Art Unit 1625